Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The Angiotensin Converting Enzyme 2 (ACE2) is the obligate receptor for the entry of SARS-CoV-2 into host cells, through high affinity interaction with the viral protein Spike. In this work, ACE2 is exploited to devise a supramolecular construct, able to deliver photoactive molecules to the viral surface. Using a modular approach, we propose a self-assembled photoactive supramolecular structure, where a biotinylated recombinant soluble human ACE2 (rshACE2) acts as a molecular decoy, to detract the viral particles from binding to the host cell receptors. The photoactive unit of the compound is streptavidin, functionalized with either a fluorophore or a photosensitizer, that spontaneously binds biotinylated rshACE2. Using STimulated Emission Depletion (STED) microscopy, direct STochastic Optical Reconstruction Microscopy (dSTORM), and Fluorescence Correlation Spectroscopy (FCS) we demonstrate binding of the supramolecular construct to the viral particles. We show that the presence of a photosensitizing unit in the assembly warrants photoinactivation of SARS-CoV-2. A > 1000-fold reduction in viral titer is observed, when the viral suspension is exposed to the supramolecular construct (100 nM, light fluence 20 J/cm). Importantly, inactivation is observed also in the dark (>1000-fold reduction of viral titer at 300 nM), through inhibition of binding of viral particles to the host cell receptors. TABLE OF CONTENTS ENTRY: The Angiotensin Converting Enzyme 2 acts as a molecular decoy able to deliver photoactive compounds for photodynamic inactivation of SARS-CoV-2.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijbiomac.2025.146128DOI Listing

Publication Analysis

Top Keywords

angiotensin converting
12
converting enzyme
12
molecular decoy
12
supramolecular construct
12
viral particles
12
viral
8
deliver photoactive
8
acts molecular
8
host cell
8
cell receptors
8

Similar Publications

Arterial Stiffness in HFpEF: From Clinical Insight to Bedside Action.

Cardiol Rev

September 2025

From the Department of General Medicine, J.S.S. Medical College, JSS Academy of Higher Education and Research, Mysuru, India.

Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases and is increasing in prevalence due to aging populations and comorbidities such as hypertension and diabetes. While echocardiography remains the diagnostic cornerstone, many patients with preserved ejection fraction present with nonspecific symptoms and ambiguous diastolic indices, leading to diagnostic uncertainty and therapeutic delay. Arterial stiffness-quantified by pulse wave velocity, augmentation index, and cardio-ankle vascular index)-is emerging as a key contributor to HFpEF pathophysiology.

View Article and Find Full Text PDF

Background: Treatment with antihypertensives in patients with advanced cancer is often continued until very late in the disease trajectory, despite a considerable risk of hypotension.

Objectives: The aim of this study was to investigate the time of deprescribing of antihypertensive agents in patients with cancer receiving palliative care during their last year of life. The monitoring of blood pressure (BP) during treatment was also studied.

View Article and Find Full Text PDF

Background: Chronic kidney disease (CKD) management was largely centered around renin-angiotensin-aldosterone system inhibitors (RAASi) optimization, until recent emergence of novel therapeutics. However, slow adoption of guideline-directed therapy leaves patients vulnerable to disease progression. In 2022, a data-driven informatics approach was introduced to track real-time adherence to best practices.

View Article and Find Full Text PDF

Background: Cushing's syndrome (CS) is associated with increased metabolic and cardiovascular (CV) risk factors and morbidities. Evidence-based guidelines for the management of these issues in active or remitted CS are not available, so best practice is derived from guidelines developed for the general population. We aimed to evaluate the awareness and practice variation for CV comorbidities of CS across Reference Centres (RCs) of the European Reference Network on Rare Endocrine Conditions (Endo-ERN).

View Article and Find Full Text PDF

Real-World Prescribing of Renal and Cardiovascular Protective Drugs in Patients With Type 2 Diabetes and Chronic Kidney Disease: Analysis of Data From a Western Australian Quaternary Hospital.

Heart Lung Circ

September 2025

Centre of Excellence for Cardiometabolic Health, Fiona Stanley Hospital, Perth, WA, Australia; Department of Cardiology, Fiona Stanley Hospital, Perth, WA, Australia; Medical School, The University of Western Australia, Perth, WA, Australia; Harry Perkins Institute of Medical Research, Perth, WA, Au

Background: In patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), sodium-glucose cotransporter 2 (SGLT2) inhibitors, semaglutide (glucagon-like peptide-1 [GLP-1] agonist), and finerenone (non-steroidal mineralocorticoid receptor antagonist) improve renal and cardiovascular outcomes. We assessed real-world prescribing of these drugs in patients with T2D and CKD.

Method: The ReDiCare project retrospectively identified patients with T2D and CKD admitted to an Australian hospital between January 2020 and September 2024 using International Statistical Classification of Diseases and Related Health Problems 10th Revision Australian Modification codes.

View Article and Find Full Text PDF